I-Mab Newsroom

ADRs End Higher; I-Mab Climbs 43%

Dow JonesApr 14 16:30 ET

ABL Bio Informuje O Licenčnej Zmluve K Platforme Podávania Liekov Do Mozgu Grabody-B so Spoločnosťou GSK Na Vývoj Nových Liekov Proti Neurodegeneratívnym Ochoreniam

PR NewswireApr 7 12:19 ET

I-Mab To Present At 24th Annual Needham Virtual Healthcare Conference; Webcast At 8:45 AM ET

RTTNewsApr 7 07:49 ET

I-Mab Positions for Growth With U.S. Focus and Innovative Cancer Treatments

TipRanksApr 4 17:31 ET

12 Health Care Stocks Moving In Friday's After-Market Session

BenzingaApr 4 17:05 ET

Needham Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsApr 4 12:31 ET · Ratings

ADT To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday

BenzingaApr 4 08:55 ET

I-Mab Price Target Maintained With a $4.00/Share by Needham

Dow JonesApr 4 07:49 ET · Ratings

HC Wainwright & Co. Maintains Buy on I-MAB, Lowers Price Target to $7

BenzingaApr 4 07:37 ET · Ratings

I-MAB Analyst Ratings

BenzingaApr 4 07:35 ET · Ratings

Promising Pipeline and Strong Financial Position Drive Buy Rating for I-Mab

TipRanksApr 4 06:26 ET · Ratings

I-Mab Reports 2024 Financial Results and Strategic Progress

TipRanksApr 3 16:28 ET

I-Mab Biopharma GAAP EPS of -$0.27 Beats by $0.07

Seeking AlphaApr 3 16:06 ET

Express News | I-MAB FY24 Adj EPADS $(0.27) Up From $(2.50) YoY

BenzingaApr 3 16:05 ET

I-Mab FY24 Loss/Shr 12c >IMAB

Dow JonesApr 3 16:03 ET

I-Mab | 6-K: Report of foreign private issuer (related to financial reporting)

SECApr 3 16:02 ET · Announcements

I-Mab | 20-F: FY2024 Annual Report

SECApr 3 16:02 ET · Announcements

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

I-Mab BiopharmaApr 3 00:00 ET

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

GlobeNewswireMar 26 07:00 ET

I-Mab Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

BenzingaMar 21 16:31 ET